I tried to see if this was posted earlier in the link library, but don't see a match.

This is an article in Genetic Engineering & Biotechnology News that is a bit old (Sep 2016) but at least does give some backing to the claim the Resverlogix and Zenith are leaders in the field of epigenetics.

Here's a link to the article.  https://www.genengnews.com/gen-articles/awaken-dormant-dna-epigenetically/5818?q=zenith 

A few excerpts if you don't want to read the whole thing.

At the forefront of the epigenetics field is a focus on the bromodomain and extra-terminal domain (BET) family of proteins that noncovalently and selectively bind with epigenetically modified (marked) amino acid residue sidechains on some histone protein subunits. Those histone protein subunits are found in chromatin.

New dedicated enterprises were founded to explore and discover the clinical manifestations of the BET interactions. Key players in bromodomain epigenetics work, especially as it relates to advanced clinical research, are Resverlogix and Zenith Epigenetics.

Donald J. McCaffrey, co-founding president and CEO of both companies, said that the firms were succeeding because they were not only adept at clinical research but also capable of unraveling biological complexities. While many other firms may have a single discovery platform,  he maintained that his company has had a dozen developed scaffolds with many compounds in the proprietary bank that are well characterized and future candidates for trials.

masila